NL
Nancy U. Lin
Highly rated in
10
conditions

Dr. Nancy U. Lin

Dana Farber Cancer Institute
Boston, MA
Highly rated in
10
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Experience:24 Years
Clinical Trials:Currently Recruiting for 5 Trials
Accepts:New PatientsMedicare
Highly rated in
10
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Nancy U. Lin's experience treating your condition:
About Dr. Nancy U. Lin

Nancy Lin is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Lin has been practicing medicine for over 24 years and is highly rated in 10 conditions, according to our data. Her top areas of expertise are Breast Cancer, Metastatic Brain Tumor, HER-2 Positive Breast Cancer, Brain Tumor, and Gamma Knife Radiosurgery. She is licensed to treat patients in Massachusetts. Lin is currently accepting new patients.

Her clinical research consists of co-authoring 255 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Nancy U. Lin it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Nancy U. Lin accepts the following insurance:

  •  Ambetter
  •  Anthem
Call to see if your plan is accepted.
Locations
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Harvard Medical School, 1999
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Womens Hospital
Newton-Wellesley Hospital
Dana Farber Cancer Institute
Brigham And Womens Faulkner Hospital
Languages Spoken
English
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Procedure, Other
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Recruiting
Publish Date: November 22, 2022
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Recruiting
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drugs: tucatinibtrastuzumab deruxtecan
Study Phase: Phase 2
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12).
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Drug, Other
Study Drugs: AnastrozoleExemestaneLetrozoleSystemic Chemotherapy
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: tucatinibcapecitabinetrastuzumab
Study Phase: Phase 2
A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: August 17, 2022
Intervention Type: Drug
Study Drugs: LapatinibHerceptin
Study Phase: Phase 2
Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drugs: ARRY-380Trastuzumab
Study Phase: Phase 1
A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis
Enrollment Status: Active, not recruiting
Publish Date: August 16, 2022
Intervention Type: Drug, Procedure
Study Drug: Atezolizumab
Study Phase: Phase 2
Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen
Enrollment Status: Completed
Publish Date: May 06, 2022
Intervention Type: Drug
Study Drugs: PaclitaxelNeulastaCyclophosphamideDoxorubicin
Study Phase: Phase 2
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: AtezolizumabPertuzumabTrastuzumab
Study Phase: Phase 2
A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: December 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: July 13, 2016
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Enrollment Status: Completed
Publish Date: May 22, 2014
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases
Enrollment Status: Terminated
Publish Date: March 14, 2013
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials -
255 Total Publications
Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases.
Journal: ESMO open
Published: September 05, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
PA
Philippe A. Armand
Dr. Philippe A. Armand
Hematology | Oncology | Hematology Oncology
Highly rated in
38
conditions
Hematology
Oncology
Hematology Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 

Philippe Armand is a Hematologist and an Oncologist in Boston, Massachusetts. Armand has been practicing medicine for over 23 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. He is licensed to treat patients in Massachusetts. Armand is currently accepting new patients.

JA
Dr. Jeremy S. Abramson
Hematology | Oncology | Hematology Oncology
Highly rated in
36
conditions
Hematology
Oncology
Hematology Oncology

Mass General Brigham

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 2.7 mi

Jeremy Abramson is a Hematologist and an Oncologist in Boston, Massachusetts. Abramson has been practicing medicine for over 23 years and is highly rated in 36 conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. He is licensed to treat patients in Massachusetts. Abramson is currently accepting new patients.

RS
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Highly rated in
39
conditions
Hematology Oncology
Hematology
Oncology

Dana Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Stone has been practicing medicine for over 42 years and is highly rated in 39 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Stone is currently accepting new patients.